FDG-PET Lymphoma Demonstration Project Invitational Workshop

Gary J. Kelloff; Daniel M. Sullivan; Wyndham Wilson; Bruce Cheson; Malik Juweid; George Q. Mills; Andrew D. Zelenetz; Sandra J. Horning; Wolfgang Weber; Daniel J. Sargent; Lori Dodd; Edward Korn; James Armitage; Richard Schilsky; Michaele Christian; Owen A. O'Connor; Sue Jane Wang; Ann T. Farrell; Richard Pazdur; Michael Graham; Richard L. Wahl; Steven M. Larson; Lale Kostakoglu; Margaret Daube-Witherspoon; Constantine Gastonis; Barry A. Siegel; Lalitha K. Shankar; David B. Lee; Howard R. Higley; Caroline C. Sigman; Daniel Carucci; David Timko; Louis J. deGennaro; Ellen Sigal; Anna Barker; Janet Woodcock

doi:10.1016/j.acra.2006.12.003

FDG-PET Lymphoma Demonstration Project Invitational Workshop

Gary J. Kelloff, Daniel M. Sullivan, Wyndham Wilson, Bruce Cheson, Malik Juweid, George Q. Mills, Andrew D. Zelenetz, Sandra J. Horning, Wolfgang Weber, Daniel J. Sargent, Lori Dodd, Edward Korn, James Armitage, Richard Schilsky, Michaele Christian, Owen A. O'Connor, Sue Jane Wang, Ann T. Farrell, Richard Pazdur, Michael GrahamRichard L. Wahl, Steven M. Larson, Lale Kostakoglu, Margaret Daube-Witherspoon, Constantine Gastonis, Barry A. Siegel, Lalitha K. Shankar, David B. Lee, Howard R. Higley, Caroline C. Sigman, Daniel Carucci, David Timko, Louis J. deGennaro, Ellen Sigal, Anna Barker, Janet Woodcock

Quantitative Health Sciences

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

The proceedings of a workshop focusing on a project to evaluate the use of fluorodeoxyglucose-positron emission tomography (FDG-PET) as a tool to measure treatment response in non-Hodgkin lymphoma (NHL) are described. Sponsored by the Leukemia & Lymphoma Society, the Foundation of the National Institutes of Health, and the National Cancer Institute, and attended by representatives of the Food and Drug Administration, the Centers for Medicare and Medicaid Services, and scientists and clinical researchers from academia and the pharmaceutical and medical imaging industries, the workshop reviewed the etiology and current standards of care for NHL and proposed the development of a clinical trial to validate FDG-PET imaging techniques as a predictive biomarker for cancer therapy response. As organized under the auspices of the Oncology Biomarker Qualification Initiative, the three federal health agencies and their private sector and nonprofit/advocacy group partners believe that FDG-PET not only demonstrates the potential to be used for the diagnosis and staging of many cancers but in particular can provide an early indication of therapeutic response that is well correlated with clinical outcomes for chemotherapy for this common form of lymphoma. The development of standardized criteria for FDG-PET imaging and establishment of procedures for transmission, storage, quality assurance, and analysis of PET images afforded by this demonstration project could streamline clinical trials of new treatments for more intractable forms of lymphoma and other cancers and, hence, accelerate new drug approvals.

Original language	English (US)
Pages (from-to)	330-339
Number of pages	10
Journal	Academic radiology
Volume	14
Issue number	3
DOIs	https://doi.org/10.1016/j.acra.2006.12.003
State	Published - Mar 2007

Keywords

FDG-PET
chemotherapy response
drug development
imaging biomarker
lymphoma

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.acra.2006.12.003

Cite this

Kelloff, G. J., Sullivan, D. M., Wilson, W., Cheson, B., Juweid, M., Mills, G. Q., Zelenetz, A. D., Horning, S. J., Weber, W., Sargent, D. J., Dodd, L., Korn, E., Armitage, J., Schilsky, R., Christian, M., O'Connor, O. A., Wang, S. J., Farrell, A. T., Pazdur, R., ... Woodcock, J. (2007). FDG-PET Lymphoma Demonstration Project Invitational Workshop. Academic radiology, 14(3), 330-339. https://doi.org/10.1016/j.acra.2006.12.003

Kelloff, GJ, Sullivan, DM, Wilson, W, Cheson, B, Juweid, M, Mills, GQ, Zelenetz, AD, Horning, SJ, Weber, W, Sargent, DJ, Dodd, L, Korn, E, Armitage, J, Schilsky, R, Christian, M, O'Connor, OA, Wang, SJ, Farrell, AT, Pazdur, R, Graham, M, Wahl, RL, Larson, SM, Kostakoglu, L, Daube-Witherspoon, M, Gastonis, C, Siegel, BA, Shankar, LK, Lee, DB, Higley, HR, Sigman, CC, Carucci, D, Timko, D, deGennaro, LJ, Sigal, E, Barker, A & Woodcock, J 2007, 'FDG-PET Lymphoma Demonstration Project Invitational Workshop', Academic radiology, vol. 14, no. 3, pp. 330-339. https://doi.org/10.1016/j.acra.2006.12.003

@article{f244bda7dadb481fb422073812965e94,

title = "FDG-PET Lymphoma Demonstration Project Invitational Workshop",

abstract = "The proceedings of a workshop focusing on a project to evaluate the use of fluorodeoxyglucose-positron emission tomography (FDG-PET) as a tool to measure treatment response in non-Hodgkin lymphoma (NHL) are described. Sponsored by the Leukemia & Lymphoma Society, the Foundation of the National Institutes of Health, and the National Cancer Institute, and attended by representatives of the Food and Drug Administration, the Centers for Medicare and Medicaid Services, and scientists and clinical researchers from academia and the pharmaceutical and medical imaging industries, the workshop reviewed the etiology and current standards of care for NHL and proposed the development of a clinical trial to validate FDG-PET imaging techniques as a predictive biomarker for cancer therapy response. As organized under the auspices of the Oncology Biomarker Qualification Initiative, the three federal health agencies and their private sector and nonprofit/advocacy group partners believe that FDG-PET not only demonstrates the potential to be used for the diagnosis and staging of many cancers but in particular can provide an early indication of therapeutic response that is well correlated with clinical outcomes for chemotherapy for this common form of lymphoma. The development of standardized criteria for FDG-PET imaging and establishment of procedures for transmission, storage, quality assurance, and analysis of PET images afforded by this demonstration project could streamline clinical trials of new treatments for more intractable forms of lymphoma and other cancers and, hence, accelerate new drug approvals.",

keywords = "FDG-PET, chemotherapy response, drug development, imaging biomarker, lymphoma",

author = "Kelloff, {Gary J.} and Sullivan, {Daniel M.} and Wyndham Wilson and Bruce Cheson and Malik Juweid and Mills, {George Q.} and Zelenetz, {Andrew D.} and Horning, {Sandra J.} and Wolfgang Weber and Sargent, {Daniel J.} and Lori Dodd and Edward Korn and James Armitage and Richard Schilsky and Michaele Christian and O'Connor, {Owen A.} and Wang, {Sue Jane} and Farrell, {Ann T.} and Richard Pazdur and Michael Graham and Wahl, {Richard L.} and Larson, {Steven M.} and Lale Kostakoglu and Margaret Daube-Witherspoon and Constantine Gastonis and Siegel, {Barry A.} and Shankar, {Lalitha K.} and Lee, {David B.} and Higley, {Howard R.} and Sigman, {Caroline C.} and Daniel Carucci and David Timko and deGennaro, {Louis J.} and Ellen Sigal and Anna Barker and Janet Woodcock",

note = "Funding Information: The meeting he was addressing, The FDG-PET Lymphoma Demonstration Project Workshop, was held at the William H. Natcher Building on the National Institutes of Health (NIH) campus on March 20, 2006, and was sponsored jointly by The Foundation of the NIH (FNIH) and L&LS. Addressing Timko{\textquoteright}s plea, the primary objective of this workshop was a clinical development plan for technology to advance the treatment of lymphoma, i.e., 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET), to measure response to chemotherapy for lymphoma. This plan will be carried out under the Oncology Biomarker Qualification Initiative (OBQI). Funding Information: Workshop was sponsored by the Leukemia & Lymphoma Society and The Foundation for the National Institutes of Health and held March 20, 2006, in Bethesda, MD. ",

year = "2007",

month = mar,

doi = "10.1016/j.acra.2006.12.003",

language = "English (US)",

volume = "14",

pages = "330--339",

journal = "Academic radiology",

issn = "1076-6332",

publisher = "Elsevier USA",

number = "3",

}

TY - JOUR

T1 - FDG-PET Lymphoma Demonstration Project Invitational Workshop

AU - Kelloff, Gary J.

AU - Sullivan, Daniel M.

AU - Wilson, Wyndham

AU - Cheson, Bruce

AU - Juweid, Malik

AU - Mills, George Q.

AU - Zelenetz, Andrew D.

AU - Horning, Sandra J.

AU - Weber, Wolfgang

AU - Sargent, Daniel J.

AU - Dodd, Lori

AU - Korn, Edward

AU - Armitage, James

AU - Schilsky, Richard

AU - Christian, Michaele

AU - O'Connor, Owen A.

AU - Wang, Sue Jane

AU - Farrell, Ann T.

AU - Pazdur, Richard

AU - Graham, Michael

AU - Wahl, Richard L.

AU - Larson, Steven M.

AU - Kostakoglu, Lale

AU - Daube-Witherspoon, Margaret

AU - Gastonis, Constantine

AU - Siegel, Barry A.

AU - Shankar, Lalitha K.

AU - Lee, David B.

AU - Higley, Howard R.

AU - Sigman, Caroline C.

AU - Carucci, Daniel

AU - Timko, David

AU - deGennaro, Louis J.

AU - Sigal, Ellen

AU - Barker, Anna

AU - Woodcock, Janet

N1 - Funding Information: The meeting he was addressing, The FDG-PET Lymphoma Demonstration Project Workshop, was held at the William H. Natcher Building on the National Institutes of Health (NIH) campus on March 20, 2006, and was sponsored jointly by The Foundation of the NIH (FNIH) and L&LS. Addressing Timko’s plea, the primary objective of this workshop was a clinical development plan for technology to advance the treatment of lymphoma, i.e., 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET), to measure response to chemotherapy for lymphoma. This plan will be carried out under the Oncology Biomarker Qualification Initiative (OBQI). Funding Information: Workshop was sponsored by the Leukemia & Lymphoma Society and The Foundation for the National Institutes of Health and held March 20, 2006, in Bethesda, MD.

PY - 2007/3

Y1 - 2007/3

N2 - The proceedings of a workshop focusing on a project to evaluate the use of fluorodeoxyglucose-positron emission tomography (FDG-PET) as a tool to measure treatment response in non-Hodgkin lymphoma (NHL) are described. Sponsored by the Leukemia & Lymphoma Society, the Foundation of the National Institutes of Health, and the National Cancer Institute, and attended by representatives of the Food and Drug Administration, the Centers for Medicare and Medicaid Services, and scientists and clinical researchers from academia and the pharmaceutical and medical imaging industries, the workshop reviewed the etiology and current standards of care for NHL and proposed the development of a clinical trial to validate FDG-PET imaging techniques as a predictive biomarker for cancer therapy response. As organized under the auspices of the Oncology Biomarker Qualification Initiative, the three federal health agencies and their private sector and nonprofit/advocacy group partners believe that FDG-PET not only demonstrates the potential to be used for the diagnosis and staging of many cancers but in particular can provide an early indication of therapeutic response that is well correlated with clinical outcomes for chemotherapy for this common form of lymphoma. The development of standardized criteria for FDG-PET imaging and establishment of procedures for transmission, storage, quality assurance, and analysis of PET images afforded by this demonstration project could streamline clinical trials of new treatments for more intractable forms of lymphoma and other cancers and, hence, accelerate new drug approvals.

AB - The proceedings of a workshop focusing on a project to evaluate the use of fluorodeoxyglucose-positron emission tomography (FDG-PET) as a tool to measure treatment response in non-Hodgkin lymphoma (NHL) are described. Sponsored by the Leukemia & Lymphoma Society, the Foundation of the National Institutes of Health, and the National Cancer Institute, and attended by representatives of the Food and Drug Administration, the Centers for Medicare and Medicaid Services, and scientists and clinical researchers from academia and the pharmaceutical and medical imaging industries, the workshop reviewed the etiology and current standards of care for NHL and proposed the development of a clinical trial to validate FDG-PET imaging techniques as a predictive biomarker for cancer therapy response. As organized under the auspices of the Oncology Biomarker Qualification Initiative, the three federal health agencies and their private sector and nonprofit/advocacy group partners believe that FDG-PET not only demonstrates the potential to be used for the diagnosis and staging of many cancers but in particular can provide an early indication of therapeutic response that is well correlated with clinical outcomes for chemotherapy for this common form of lymphoma. The development of standardized criteria for FDG-PET imaging and establishment of procedures for transmission, storage, quality assurance, and analysis of PET images afforded by this demonstration project could streamline clinical trials of new treatments for more intractable forms of lymphoma and other cancers and, hence, accelerate new drug approvals.

KW - FDG-PET

KW - chemotherapy response

KW - drug development

KW - imaging biomarker

KW - lymphoma

UR - http://www.scopus.com/inward/record.url?scp=33847249498&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847249498&partnerID=8YFLogxK

U2 - 10.1016/j.acra.2006.12.003

DO - 10.1016/j.acra.2006.12.003

M3 - Article

C2 - 17307666

AN - SCOPUS:33847249498

SN - 1076-6332

VL - 14

SP - 330

EP - 339

JO - Academic radiology

JF - Academic radiology

IS - 3

ER -

FDG-PET Lymphoma Demonstration Project Invitational Workshop

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this